Compare · BSX vs IINN
BSX vs IINN
Side-by-side comparison of Boston Scientific Corporation (BSX) and Inspira Technologies Oxy B.H.N. Ltd. (IINN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and IINN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.26B, about 4329.9x IINN ($16.7M).
- Over the past year, BSX is down 53.1% and IINN is down 68.0% - BSX leads by 14.8 points.
- BSX has been more active in the news (10 items in the past 4 weeks vs 8 for IINN).
- BSX has more recent analyst coverage (25 ratings vs 2 for IINN).
- Company
- Boston Scientific Corporation
- Inspira Technologies Oxy B.H.N. Ltd.
- Price
- $49.86+1.73%
- $0.38+0.51%
- Market cap
- $72.26B
- $16.7M
- 1M return
- +9.58%
- -34.36%
- 1Y return
- -53.13%
- -67.98%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 10
- 8
- Recent ratings
- 25
- 2
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
Latest BSX
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
- Director Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)
- SEC Form 10-Q filed by Boston Scientific Corporation
Latest IINN
- SEC Form 424B5 filed by Inspira Technologies Oxy B.H.N. Ltd.
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- QTREX Announces Pricing of a $10 Million Registered Direct Offering of Ordinary Shares
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- QTREX's Patent-Pending Technology Achieves First Direct Conversion of 3D-Printed Insulation into Graphene-Like Carbon to Protect Quantum Processors
- QTREX and U.S. Department of Defense Laboratory Target Q4 2026 to Formalize Joint Quantum Development Program
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- SEC Form EFFECT filed by Inspira Technologies Oxy B.H.N. Ltd.
- QTREX Proprietary Quantum Interconnect Platform Exceeds Performance Requirements Established by Strategic Partners
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.